| Recent advances in cell therapy for AML/MDS |
|
International Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| DNA methylation status at diagnosis in MDS predicts response to azacitidine |
|
Journal of Clinical Investigation |
Myelodysplastic Syndromes (MDS) |
| Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials |
|
Communications Medicine |
Myelodysplastic Syndromes (MDS) |
| American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1 |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Expert Consensus on the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH): An Algorithmic Approach in an Era of New Treatments |
|
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Co |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Comparison of Late Effects and Quality of Life by Donor Type in Long-Term Survivors of Severe Aplastic Anemia after Hematopoietic Cell Transplantation |
|
Transplant Cell Therapy |
Aplastic Anemia |
| Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML |
|
Transplant Cell Therapy |
Myelodysplastic Syndromes (MDS) |
| Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial |
|
Blood |
Aplastic Anemia |
